The phylogeny and evolution of Epstein-Barr virus (EBV) genetic variation are poorly understood. EBV latent membrane protein-1 (LMP-1) gene sequences are especially heterogeneous and may be useful as a tool for EBV genotype identification. Therefore, LMP-1 sequences obtained directly from EBV-infected human tissues were examined by PCR amplification and cloning. EBV genotypes were defined as "strains" from among 22 identified LMP-1 sequence patterns. Three molecular mechanisms were identified by which genetic diversity arises in the LMP-1 gene: point mutation, sequence deletion or duplication, and homologous recombination. The rate of LMP-1 gene evolution was found to be accelerated by coinfection with multiple EBV strains. The results of this study refine our understanding of LMP-1 sequence variation and enable accurate discrimination between independent EBV infection events and the consequence of intrahost EBV evolution. Thus, this LMP-1 sequencebased approach to EBV molecular epidemiology will facilitate the study of intrahost EBV infection, coinfection, and persistence.
lymphocytic and epithelial reservoirs of EBV infection during viral latency and reactivation remains to be elucidated [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Second, the importance of multiple EBV infections in lifelong persistence and disease pathogenesis is unknown. Coinfection with multiple EBV genotypes is common in immunocompromised persons [13] [14] [15] [16] [17] ; yet, the prevalence of EBV coinfection is uncertain in healthy persons [18] [19] [20] [21] [22] [23] . Some data suggest that the epithelial and lymphocytic tissues of a single individual may harbor different EBV genotypes [14, 15, 18, 19, 24, 25] . Understanding EBV coinfection and persistence is critical for understanding disease pathogenesis and for developing an effective EBV vaccine. Molecular epidemiology studies of intrahost EBV infection are needed to address these important issues.
Previously, EBV molecular epidemiology has been studied by restriction fragment length polymorphisms (RFLPs) [1, 20, 21, [26] [27] [28] [29] and by EBV nuclear antigen protein size variation (EBNotype) [1, 19, 30, 31] of EBV isolates that transform B lymphocytes in vitro. However, these methods are limited by three important constraints. Selection bias toward transformation-competent EBV isolates underrepresents the full range of EBV strains and variants present in vivo [24, 32] ; viral recombination in repetitive sequences during productive EBV replication confounds some of the RFLP and EBNotype definitions of strain identity [13, 25, 30, 33, 34] ; and the RFLP and EBNotyping techniques fail to detect the full range of EBV genomic heterogeneity present in nature [13, 25, 34] . Recent studies suggest that EBV genotypes may be more accurately identified by specific DNA sequence patterns at defined gene loci [25, [34] [35] [36] .
The EBV proto-oncogene latent membrane protein-1 (LMP-1) is believed to play an important role in the pathogenesis of many EBV-associated diseases [37] [38] [39] [40] [41] . Sequences in the LMP-1 carboxy-terminus influence cell growth, differentiation, and apoptosis by interacting with the tumor necrosis factor receptor-associated signaling factors and the NF-kB family of transcriptional regulators [42] [43] [44] [45] [46] [47] . LMP-1 carboxy-terminal sequences manifest a high degree of sequence heterogeneity. However, the phylogeny, evolutionary origin, and functional significance of LMP-1 sequence variation are poorly understood.
Therefore, LMP-1 sequences obtained directly from human tissues were studied to identify LMP-1 sequence patterns that define specific EBV genotypes and to identify the molecular mechanisms that generate LMP-1 sequence variation in vivo. The goal of this work was to develop a new LMP-1 sequence-based approach to EBV molecular epidemiology that would facilitate the study of intrahost EBV infection.
Materials and Methods
Preparation of human tissue DNA. Clinical tissue specimens were obtained for this study from 14 research subjects. Tongue tissues were obtained by incisional biopsies of the 3 mm ϫ 8 mm lateral tongue. Peripheral blood lymphocytes were obtained by centrifugation of 20 mL of venous blood through lymphocyte separation media (Organon Teknika, Durham, NC). DNA was extracted from tongue biopsy tissue and peripheral blood lymphocytes in 4 M guanidine isothiocyanate and isolated by centrifugation on a cesium chloride step gradient [37] . Throat washes were obtained by having the subjects gargle 25 mL of sterile PBS. The throat wash cell pellet was digested with proteinase K, 0.1 mg/mL, and Tween 20, 0.5%, before polymerase chain reaction (PCR) amplification.
PCR amplification. PCR amplification of the LMP-1 gene sequences was done with primer 1 (ACGAGGAATTCTTAGTCA-TAGTAGCTTAGCTGAAC; genome coordinates 168160-168183 [48] ) and primer 2 (ACGAGGGATCCGGACAACGACACAGT-GATGAACAC; genome coordinates 168759-168736 [48] ). The reaction mixture consisted of 2 U of Vent polymerase (thermostable DNA polymerase with 5 -3 exonuclease proofreading ability; New England Biolabs, Beverly, MA); a 1:10 dilution of 10ϫ reaction buffer as supplied with the Vent polymerase; 200 mM each dATP, dCTP, dGTP, and dTTP; 0.5 pM each primer; and 0.1-1.0 mg of target genomic DNA in 50-mL or 100-mL reaction volumes. Amplification proceeded for 40 cycles with denaturation at 98ЊC for 1 min, annealing at 55ЊC for 30 s, and extension at 72ЊC for 1 min. For some specimens, a second round of 40 cycles of amplification was required to generate sufficient quantities of product to clone. PCR products were analyzed by 1.2% agarose gel electrophoresis and ethidium bromide staining. Standard techniques were used to prevent and detect in vitro contamination of the PCR reactions.
PCR amplification of the LMP-1 11-amino acid (33-bp) variable repeat sequences (to determine the number of repeat units present) was achieved with primer 3 (ACGAGGAATTCCAGCA-GAGTCGCTAGGG; genome coordinates 168375-168394 [48] ) and primer 4 (ACGAGGGATCCTAGGCGCACCTGGAGGT-GGT; genome coordinates 168598-168577 [48] ). The reaction mixture for primers 3 and 4 was identical to that for primers 1 and 2 except for a 6-mM concentration of MgSO 4 . Amplification proceeded for 15 cycles when amplifying 1 mL of cloned DNA or for 40 cycles when amplifying 0.1-1.0 mg of genomic DNA, with denaturation at 98ЊC for 1 min, annealing at 57ЊC for 30 s, and extension at 72ЊC for 1 min. The sizes of the PCR products were determined by 6% polyacrylamide gel electrophoresis and ethidium bromide staining.
Cloning of PCR products. The complete products of each PCR amplification reaction were cloned into plasmid vector pGem3Z (Promega, Madison, WI), by use of EcoRI and BamHI restriction enzyme sites within PCR primers 1 and 2, respectively. Ligated PCR products and vectors were transformed into Escherichia coli DH5aF IQ, which is genotype recA(Ϫ) and deficient for in vitro recombination (GibcoBRL, Grand Island, NY). Bacterial colonies containing the appropriate cloned PCR products were identified by in situ hybridization on a nitrocellulose membrane with a [g- 32 P] end-labeled oligonucleotide probe (CCAGAAGAACCCAAA-AGCAG; genome coordinates 168218-168237 [48] ) and autoradiography.
DNA sequencing. The LMP-1 sequences of 265 clones from 29 clinical specimens from the 14 research subjects were determined for the regions downstream and upstream of the 11-amino acid variable repeats. Plasmid DNA for sequencing was extracted from bacterial cell cultures by means of alkaline lysis [49] . DNA sequence was obtained using the dideoxynucleotide chain-termination method with [a- Phylogenetic analysis of EBV sequences. The NEIGHBOR neighbor-joining computer program included in the PHYLIP package [50] was used to calculate bootstrap values and to construct consensus phylogenetic trees for 64 downstream and 39 upstream sequences. Between 2 and 8 different substrain examples of each sequence pattern were selected to represent the most conservative cases and the most divergent cases available for both the downstream and upstream analyses.
Results
Defining EBV strains by LMP-1 sequence analysis. The LMP-1 carboxy-terminal DNA sequences were amplified and cloned from 29 clinical specimens collected from 14 research subjects with EBV infection (table 1). Visual analysis of the nucleotide and predicted amino acid sequences from 265 clones identified five loci of sequence heterogeneity (figure 1). Sequence variation in the downstream and the upstream sequences (figure 1, loci 1 and 2) was analyzed to develop strain sequence definitions.
Similar amino acid and nucleotide sequences were repeatedly Five loci of sequence heterogeneity identified in carboxyterminus of latent membrane protein-1 (LMP-1) gene of EBV (circled numerals). 1, amino acid sequence pattern downstream of repeat region; 2, amino acid sequence pattern upstream of repeat region; 3, presence or absence (deletion) of aa 343-352; 4, no. of 11-amino acid repeat units present in repeat region; and 5, presence (insertion) or absence of aa 276-280 (one-half repeat unit) in repeat region. Loci 1 and 2 were used to identify sequence patterns that defined EBV strains. Sequence variation at loci 3-5 evolves rapidly through genetic recombination. These three loci were less reliable markers of EBV genetic identity. Amino acids are numbered on basis of lymphoblastoid cell line EBV isolate B958 [48] . detected in clones from different subjects and different geographic locations. Common amino acid substitutions were identified among the groups of similar sequences. On the basis of these sequence consistencies, 20 different sequence patterns were defined for the downstream and upstream sequences. These 20 sequence patterns were then compared with 427 published LMP-1 sequence examples [36, . Seventeen of the 20 sequence patterns were also detected among the published LMP-1 sequences. Two additional sequence patterns not found among the 265 clones were subsequently defined at the downstream locus from among the published LMP-1 sequences.
In total, 22 LMP-1 amino acid sequence patterns were defined at the downstream and upstream sequence loci (figure 2). Each sequence pattern was detected in at least 3 subjects and from at least two geographic locations (figure 3). These 22 sequence patterns were sufficient to categorize all currently known LMP-1 carboxy-terminal sequences. In this study, EBV genotypes were distinguished as a "strain" by the combination of downstream and upstream sequence patterns present conjointly in the LMP-1 gene. Phylogenetic analysis of EBV strains. Phylogenetic analyses (data not shown) were conducted for 103 sequences representing multiple examples of each of the 22 sequence patterns defined in figure 2. Three evolutionary lineages were identified among the downstream patterns. A common ancestor is shared by patterns B958 and 1; another is shared by patterns 2a/b/c, 3, 4, 5, and 6; and another is shared by patterns 7, 8, and 9. Among the upstream sequences, patterns B958, A, and B evolved from a common ancestor and are closely related to a separate lineage that gave rise to patterns F2 and G. Sequence patterns C and D evolved from another common ancestor, while patterns E, F1, and H each represent additional independent lineages. Although the evolutionary distances between sequence patterns were relatively small, these phylogenetic analyses demonstrated a clear monophyletic origin for each of the 22 sequence patterns, further validating their use in EBV genotype identification.
Molecular epidemiology of EBV strains. Epidemiologic analysis of the 265 cloned and the 427 published LMP-1 sequences was done to determine the geographic distribution and disease associations of EBV strains (figure 3). There was no obvious geographic restriction to any of the sequence patterns. Downstream patterns B958, 2a, 2c, 3, and 7, and upstream patterns B958, C, D, and F1 appear to be especially widespread throughout the world. Although particular strains may be common in some geographic locations, multiple EBV strains appear to cocirculate in most areas. Additionally, there was no unique phosphorylation site; necrosis factor receptor-associated factor binding site; degradation F ϭ putative ϭ tumor arrow ϭ protein cleavage site. 1, Patterns that were identified among 265 clones and 427 published LMP-1 sequences; 2, patterns that were identified only among 265 clones; 3, patterns that were identified only among 427 published LMP-1 sequences (pattern 6 [58, 60, 61, 63] ; pattern 8 [36, [69] [70] [71] ). Consensus DNA and amino acid sequences for these 22 sequence patterns are also available in GenBank library under accession nos. AF096840-AF096861. association between any sequence pattern and any specific disease manifestation examined. Most sequence patterns were associated with asymptomatic infection as well as with multiple diseases.
Evolution of substrain sequence variation: point mutation. Sequence analysis of the 265 clones demonstrated occasional random nucleotide changes occurring in the context of the strain-defining sequence pattern present (data not shown). Random changes were unique to single clones, or unique to multiple clones of the same strain obtained from a single research subject. These additional changes were termed "substrain" sequence variation.
To determine the PCR nucleotide error rate for this study [73] , cloned LMP-1 DNA of known sequence was either amplified directly or spiked into human DNA before amplification. Multiple amplifications were done using a wide range of initial template quantities and either 40 or 80 (40 ϩ 40) total cycles. Amplification products were cloned, and 26,000 nucleotides from 65 clones were examined. The error rate was 0.05%-0.10%, consistent with published data for Vent DNA polymerase [74] . Thus, for the clones obtained from the research subjects, a 10.10% nucleotide substitution frequency suggested the presence of substrain sequence variation in vivo.
Substrain sequence variation in vivo was detected more often with EBV coinfection (table 2). Clones obtained from tongue tissues infected with a single EBV strain demonstrated a mean nucleotide substitution frequency of 0.137%, not significantly different from the PCR error rate. However, clones from research subjects harboring multiple EBV strains in tongue tissues demonstrated a mean nucleotide substitution frequency of 0.315%. The difference between these two numbers was highly statistically significant (table 2) .
Nucleotide substitutions were examined longitudinally in 104 same-strain clones from 3 research subjects (data not shown). The mean number of substitutions per clone did not increase, and specific substitutions did not necessarily persist or accumulate over time. Notably, sequence patterns did not evolve directionally, from a particular strain identity into another.
Grouped analysis of nucleotide substitutions in clones of all strains demonstrated an overall 77% rate of nonsynonymous substitution and a transition-transversion ratio of 1.3:1. These numbers exceed expectations based on chance mutation alone and suggest that positive selection drives the evolution of substrain LMP-1 sequence variation in vivo.
The LMP-1 protein phosphorylation site at 313 S [75] was altered in three sequence patterns (figure 2). Other LMP-1 protein functional sites appear to be conserved by substrain sequence evolution in vivo. The frequency of nucleotide substitution equaled the PCR nucleotide error rate at three other functional sites: phosphorylation (324 T [75] tified in pattern 7 from a particular research subject and in pattern B958 from another subject. In the third case, an unusual duplication of aa 343-352 was identified in pattern 5 from another research subject (data not shown). In each case, the variant clones represented a tiny minority of the many same-strain clones obtained from each research subject. Although the possibility of independent infection events cannot be excluded, these data suggest that the deletion and duplication variants arose in vivo in these 3 research subjects. Thus, intrastrain recombination may generate deletions or duplications of aa 343-352 in the context of any sequence pattern.
Evolution of aa 250-298: intrastrain homologous recombination.
Variation in the LMP-1 11-amino acid unit repeat region ( figure 1, locus 4) has been used as a marker of EBV genetic identity [14, 15, [83] [84] [85] . However, recombination in EBV repetitive sequences introduces new variation and confounds genetic identity [25, 30, 33, 34, 36] .
In this study, examination of 227 of the 265 clones demonstrated that different strains frequently have the same number of repeats and that clones of the same strain frequently have different numbers of repeats (figure 4). Direct amplification of the repeat region from tongue tissue DNA was done for 4 research subjects infected with a single EBV strain. In each case, direct amplification produced a heterogeneous population of products that accurately reflected the variation represented by the clones obtained from the same research subject (data not shown). Although the possibility of independent infection events cannot be excluded, these data suggest that intrastrain recombination in vivo generates repeat region variation. Clearly, the number of LMP-1 repeats does not uniquely identify an EBV strain.
Evolution of aa 250-298: interstrain homologous recombination. Clones from 6 research subjects contained interstrain recombinations of downstream and upstream sequences from the multiple coinfecting strains present (table 3) . To determine the PCR recombination error rate for this study, equal quantities of tongue tissue DNA from 2 research subjects (single strain 5-D and single strain 2a-F1) were mixed, amplified, cloned, and sequenced. Two (9%) of 22 clones contained an artifactual hybrid of sequences from these 2 strains. Twentythree (23%) of the 102 clones obtained from the 6 research subjects demonstrated interstrain recombinations (table 3) . Although the difference between these two numbers was not statistically significant, these data suggest that some of the LMP-1 hybrid clones represent interstrain recombinations that occurred in vivo among the coinfecting EBV strains.
Evolution of aa 276-280: interstrain homologous recombination. The presence (insertion) of LMP-1 aa 276-280 (figure 1, locus 5) in the LMP-1 repeat region is characteristic of strains B958-B958 (B958 lymphoblastoid cell line) and 1-G (Raji Burkitt's lymphoma) [36] . Phylogenetic analyses demonstrating a common ancestor for these 2 strains suggests that the insertion arose only once, early in the evolution of the LMP-1 gene.
In this study, examination of 227 of the 265 clones demonstrated the presence of aa 276-280 only in strains B958-B958 and 1-G, or in interstrain recombinants containing sequences from these strains (data not shown). In 2 research subjects, strains 1-B958 and 2a-G contained aa 276-280. However, clones containing parental strains B958-B958 or 1-G were not identified, suggesting that strains 1-B958 and 2a-G previously arose through interstrain recombination and then independently infected these 2 research subjects de novo.
Discussion
We examined natural sequence variation in the EBV LMP-1 gene carboxy-terminus and developed a sequence-based approach to EBV genotype identification in vivo. EBV genotypes were defined as strains by the combination of specific LMP-1 amino acid sequence patterns present at loci downstream and upstream of the repeat region. Phylogenetic analyses supported the use of these sequence patterns as markers of EBV genetic identity. Twenty-two defined patterns were sufficient to categorize all currently known LMP-1 carboxy-terminal sequences. LMP-1 sequence patterns represent stable EBV genotypes that probably evolved in the distant past [86, 87] . Each EBV strain may reflect the immunogenetic composition of the local human population in which it originally evolved [88] [89] [90] [91] . The current worldwide distribution of most EBV strains likely reflects the increased scale of human migration over the last 2 centuries.
One approach to understanding the complex epidemiology and pathogenesis of the many EBV-associated diseases is to examine potential associations between specific EBV genotypes and disease phenotypes [21, 53, [92] [93] [94] [95] [96] . Although the LMP-1 protein is expressed in many EBV-associated diseases [37] [38] [39] [40] [41] , the lack of association between any single LMP-1-defined NOTE. Apparent interstrain recombinant variants were detected in tissue specimens from 6 research subjects coinfected with multiple EBV strains. Clones were determined to be interstrain recombinants on basis of unusual combination of downstream and upstream sequences present in that subject and absence of that specific pattern combination as independent strain in other subjects or among published latent membrane protein-1 (LMP-1) sequences. In few cases (subject 4, 7-B958; subject 7, 5-B958; subject 10, B958-C, B958-F1), insufficient number of clones was examined to exclude possibility of de novo infection with presumed recombinant strains. Twenty-three (23%) of 102 clones examined from these coinfected tissues demonstrated interstrain recombination, while only 2 (9%) of 22 control clones sustained artifactual interstrain recombination. Observed difference between groups was 14 ( strain and any specific EBV-associated disease demonstrates that the clinical outcome of EBV infection cannot be predicted by LMP-1 sequence variation alone. However, these data do not exclude the possibility that different LMP-1-defined strains share common pathogenic features that predispose to a diseaseproducing phenotype.
Accurate molecular epidemiology studies require reliable methods to identify individual EBV genotypes. The number of genotypes definable by LMP-1 sequence variation far exceeds that of any other EBV gene studied to date, including EBNA-1, EBNA-2, LMP-2, BZLF1, and BHRF1 [34, [97] [98] [99] [100] . Thus, the LMP-1 gene provides the most discriminating genetic locus for EBV genotype identification and the highest degree of sensitivity and specificity for molecular epidemiology studies of EBV infection. An LMP-1 sequence-based approach to EBV molecular epidemiology would be especially useful for studying intrahost EBV infection in immunocompromised persons, a group manifesting a high prevalence of coinfection with multiple EBV strains and high rates of productive EBV replication.
During productive EBV replication, new LMP-1 sequence diversity arises in the context of preexisting sequence patterns. LMP-1 sequences do not readily evolve directionally from one strain into another. Three types of genetic variation contribute to the evolution of the LMP-1 gene.
The first is point mutation. Substrain nucleotide sequence variation either reflects the geographic variation of a strain or arises de novo during productive EBV replication. Although the error rate of EBV DNA polymerase is not known, productive EBV replication increases the opportunity for new point mutations to arise. Some point mutations appear to be pre-served by positive selective evolutionary pressure. Additionally, negative selective pressure appears to conserve specific amino acids that are known to be critical for LMP-1 protein function.
The second is sequence deletion and duplication. EBV genotypes with LMP-1 deletions exist in the human population as independent strains [57, 58, 61-63, 69, 71, 78-81] . However, LMP-1 aa 343-352 can undergo either deletion or duplication during productive EBV replication. These intrastrain recombinant variants may arise through misalignment of the flanking 9-nucleotide direct repeats during replication [69] . Thus, the status of aa 343-352 is unreliable as the sole marker of EBV genetic identity.
The third is homologous recombination. Intrastrain homologous recombination occurs in the LMP-1 repeat region, as well as in other repetitive EBV sequences [30, 33, 34] . The progeny of EBV productive replication frequently have a different number of LMP-1 repeat units than does the parental strain. Thus, the number of LMP-1 repeat units present does not uniquely identify an EBV strain, especially when EBV productively replicates in vivo. Interstrain homologous recombination occurs during EBV coinfection and productive replication, creating hybrid LMP-1 variants. Similar to intertypic EBV recombinants [25, 101, 102] , LMP-1 recombinant variants may also persist in the human population as new EBV strains. The presence of aa 276-280 in hybrid strains containing B958-B958 or 1-G sequences suggests an interstrain recombinant evolutionary history for those EBV genomes [36, 65, 67, 70] .
The results of this study suggest that EBV coinfection accelerates the rate of intrahost evolution of the EBV genome.
Positive selective pressure appears to increase the prevalence of substrain sequence variation during EBV coinfection of tongue tissue. EBV coinfection and interstrain recombination generate hybrid genotypes that persist as new EBV strains. Evolutionary theory of host-parasite interaction may explain these observations.
Interhost selection achieves a balance between parasite transmission efficiency and virulence [103] [104] [105] . However, intrahost selection favors the most reproductively successful parasite strains, substrains, or variants, even at the expense of increased virulence [106] [107] [108] . Mathematical models suggest that coinfection and intrahost selection also sustain a genetically more heterogeneous parasite population than that of single infection [109] [110] [111] . The increased LMP-1 sequence diversity observed with EBV coinfection may be explained by positive selection of new EBV substrains and variants that possess higher levels of reproductive fitness.
Immunocompromised hosts provide an ideal environment for rapid EBV evolution. Immunodeficiency permits coinfection with multiple EBV types and strains [13, 14, 16, 20, 22, 25, 34, 112] . Persistent productive EBV replication provides an opportunity for new genetic variation to arise [113] [114] [115] [116] [117] [118] . Decreased host immunosurveillance permits selection based on EBV replication characteristics rather than evasion of the host immune response [88, 119] .
The implications of evolutionary changes in the LMP-1 gene are unclear. It is unknown whether new LMP-1 substrains or interstrain recombinant variants are more pathogenic or specifically responsible for the high incidence of EBV-associated disease in immunocompromised persons. It is possible to speculate that new LMP-1 sequence variation may alter the function or the immunogenicity of the LMP-1 protein, thus altering its role in disease pathogenesis. However, few data currently exist to support such hypotheses. Alternatively, the evolution of LMP-1 sequence variation may simply reflect other evolutionary changes in the EBV genome that influence EBV pathogenesis to a greater degree. Natural selection acts on the phenotype of the virus as a whole, rather than on individual genes in isolation.
In conclusion, this study demonstrates that EBV genotypes can be classified in terms of strain, substrain, or recombinant variant, based on sequence patterns in the LMP-1 gene. This study also identifies three molecular mechanisms that contribute to the evolution of LMP-1 sequences in vivo and documents the importance of EBV coinfection in the process of EBV evolution. This study demonstrates a lack of association between specific LMP-1-defined strains and specific disease manifestations, suggesting that EBV pathogenesis is multifactorial in nature. Therefore, we suggest that future epidemiologic studies of EBV-associated diseases focus on other EBV genes as well as potential environmental, immunologic, and host genetic cofactors.
Most importantly, this study introduces a new approach to the molecular epidemiology of EBV infection that should be especially advantageous for the study of intrahost EBV infection. First, amplification of LMP-1 sequences directly from infected tissues detects a broader range of the EBV genetic heterogeneity present in vivo than do other methods. Second, understanding LMP-1 sequence variation and its evolution enables accurate discrimination between independent EBV infection events and the consequences of intrahost EBV evolution. Thus, we propose that LMP-1 amplification, cloning, and sequencing will be powerful tools for the study of intrahost EBV infection, especially the pathogenesis of EBV coinfection and the mechanisms of EBV persistence.
